

BIOMARIN PHARMACEUTICAL INC

Form 8-K

December 31, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): December 24, 2015**

**BioMarin Pharmaceutical Inc.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware  
(State or Other Jurisdiction**

**of Incorporation)**

**000-26727  
(Commission**

**File Number)  
770 Lindaro**

**68-0397820  
(I.R.S. Employer**

**Identification No.)**

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

**San Rafael, CA 94901**

**(Address of Principal Executive Offices, Including Zip Code)**

**(415) 506-6700**

**(Registrant's Telephone Number, Including Area Code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 24, 2015, Kenneth M. Bate notified BioMarin Pharmaceutical Inc. (the Company ) that he is resigning from the Company s Board of Directors, effective immediately due to conflict with other professional activities. Mr. Bate confirmed that he is not resigning as a result of any dispute or disagreement with the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOMARIN PHARMACEUTICAL INC.**

Date: December 31, 2015

By: /s/ G. Eric Davis  
G. Eric Davis  
Senior Vice President, General Counsel &  
Secretary